Objectives: To study the outcomes of antituberculosis treatment in HIV/AIDS patients on antiretroviral therapy (ART).
Material And Method: This retrospective cohort study was performed by reviewing medical records of 166 patients co-infected with tuberculosis (TB) and HIV in a hospital in Thailand seen between January 2005 and February 2008. These patients were treated with both antituberculosis (antiTB) and antiretroviral drugs (ART) and were followed for 18 months after the beginning of antiTB.
Results: Total 166 HIV patients with TB on ART and anti tuberculosis drugs were analyzed. The median age of patients was 36 years (20-72). Sixty-nine (41.6%) patients had pulmonary TB and 97 (58.4%) disseminated TB. Among them, 127 (76.5%) were cured and 15 (9.0%) had unsuccessful treatment. Median time for successful treatment was 10.8 months (6-32) during 18 months follow-up. There was no statistically significant difference in outcome of tuberculosis between the NVP and EFV base regimens in combination with rifampicin (5.4% vs. 10.8%, p = 0.751).
Conclusion: Majority of HIV patients on ARTwith tuberculosis were successfully treated with antiTB drugs with median time of 10.8 months and no significant difference ofadverse events reported between NVP and EFV
Download full-text PDF |
Source |
---|
Clin Infect Dis
December 2024
III Infectious Disease Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy.
Background: Under standard therapies, the incidence of drug-induced liver injury (DILI) in patients with tuberculosis ranges from 2% to 28%. Numerous studies have identified the risk factors for antituberculosis DILI; however, none have been conducted in a multiethnic real-world setting. The primary outcome of the current study was to identify the risk factors that could be used as the best predictors of DILI in a multiethnic cohort.
View Article and Find Full Text PDFInfect Drug Resist
December 2024
Pulmonary Diseases Department, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, People's Republic of China.
Background: Tuberculosis (TB) among women and infants during the perinatal period is not rare, particularly in countries with a high TB burden. And the risk would increase significantly following in vitro fertilization-embryo transfer (IVFET). Worse still, TB in this stage is apt to develop into severe forms in women and neonates, such as disseminated TB or tuberculous meningitis (TBM).
View Article and Find Full Text PDFJ Med Case Rep
December 2024
RineCynth Advisory Limited, Kampala, Uganda.
Background: Pulmonary carcinoids are rare neuroendocrine tumors accounting for less than 1% of all lung cancers. They are classified into two subcategories; typical and atypical carcinoids with the latter tending to grow faster. Historically, open thoracotomy was the standard approach for pulmonary resection.
View Article and Find Full Text PDFBMC Infect Dis
December 2024
Department of Orthopedics, Leshan People's Hospital, No. 238 Baita Street, Shizhong District, Leshan, Sichuan Province, China.
Background: Fungal spondylitis often occurs in patients with immune dysfunction, and its diagnosis and treatment pose certain challenges. However, even in immunocompromised patients, Aspergillus spondylitis remains rare. This case reports the diagnostic and therapeutic experience of fungal spondylitis in a patient with consolidated cirrhosis and no significant immune impairment.
View Article and Find Full Text PDFCurr Pharm Des
December 2024
Materials Laboratory, School of Mechanical Engineering, Yeungnam University, Gyeongsan-38541, Republic of Korea.
Hepatotoxicity is a critical health hazard, primarily contributing to the increased incidence of deaths globally. The liver is one of the major and extremely vital organs of the human body. Autoimmune diseases, viruses, exposure to toxicants such as carcinogens, and changes in eating habits can all cause liver problems, among other things.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!